De Novo Drug Design
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Computer-assisted molecular design supports drug discovery by suggesting novel chemotypes and compound modifications for lead structure optimization. While the aspect of synthetic feasibility of the automatically designed compounds has been neglected for a long time, we are currently witnessing an increased interest in this topic. Here, we review state-of-the-art software for de novo drug design with a special emphasis on fragment-based techniques that generate druglike, synthetically accessible compounds. The importance of scoring functions that can be used to predict compound reactivity and potency is highlighted, and several promising solutions are discussed. Recent practical validation studies are presented that have already demonstrated that rule-based fragment assembly can result in novel synthesizable compounds with druglike properties and a desired biological activity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
SAR Index: Quantifying the Nature of Structure−Activity Relationships
Peltason, L., & Bajorath, J. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0705713 · Cited by 201
Ligand efficiency and fragment-based drug discovery
Bembenek, S. D., Tounge, B. A., & Reynolds, C. H. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.007 · Cited by 196
Knowledge-Based Approach to de Novo Design Using Reaction Vectors
Patel, H., Bodkin, M. J., Chen, B., & Gillet, V. J. (2009) · Journal of Chemical Information and Modeling · doi:10.1021/ci800413m · Cited by 82
Cited by
Designing antimicrobial peptides: form follows function
Fjell, C. D., Hiss, J. A., Hancock, R. E. W., & Schneider, G. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3591 · Cited by 2,035
Self-citationEnumeration of 166 Billion Organic Small Molecules in the Chemical Universe Database GDB-17
Ruddigkeit, L., van Deursen, R., Blum, L. C., & Reymond, J.-L. (2012) · Journal of Chemical Information and Modeling · doi:10.1021/ci300415d · Cited by 1,505
Machine Learning in Drug Discovery: A Review
Dara, S., Dhamercherla, S., Jadav, S. S., Babu, C. M., & Ahsan, M. J. (2022) · Artificial Intelligence Review · doi:10.1007/s10462-021-10058-4 · Cited by 792
A Structure-Based Drug Discovery Paradigm
Batool, M., Ahmad, B., & Choi, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112783 · Cited by 744
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Metadata
- Authors
- Hartenfeller, M., & Schneider, G.
- Venue
- Methods in Molecular Biology
- Publisher
- Humana Press
- Published
- 2010
- Volume
- 672
- Pages
- 299-323
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W1592371672
- Cited by
- 154
- References
- 3
- FWCI
- 21.94
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: De Novo Drug Design. https://app.cochat.ai/papers/10.1007/978-1-60761-839-3_12
- The paper
- Hartenfeller, M., & Schneider, G. (2010). De Novo Drug Design. Methods in Molecular Biology. https://doi.org/10.1007/978-1-60761-839-3_12
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.